Mahadi Baig, Vice President, Head of Solid Tumors, US Medical Affairs at Johnson and Johnson, posted on LinkedIn:
“We’re proud to share the first results from our investigational study in recurrent or metastatic head and neck squamous cell carcinoma – a patient population facing limited treatment options.”
Emrullah Yilmaz shared a post by Mahadi Baig, adding:
“Excited to see our study presented at ESMO25, contributing to ongoing efforts to improve outcomes for patients with head and neck cancers. Deep gratitude to the investigators and the patients whose participation makes this possible.”
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
